BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

BridgeBio Pharma announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 – 28, 2023.

ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR). BridgeBio will host an investor call with members of the Company’s leadership team as well as Julian Gillmore, M.D., Ph.D., on Monday, August 28 at 8:30 am ET to discuss the results shared at the meeting.

In addition to presenting the results from ATTRibute-CM, BridgeBio will also present a moderated poster on the observed near-complete TTR stabilization of acoramidis in patients with variant transthyretin amyloidosis, and will host a satellite symposium to discuss the evolving landscape of ATTR-CM.